Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Geomagnetic storm grounds launch of Mars space weather satellites12.11.2025 - 2What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis09.01.2026
- 3Ober Gabelhorn glacier reveals remains of man missing for over three decades17.11.2025
- 4'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog13.11.2025
- 5Why do people have baby teeth and adult teeth?10.01.2026
- 5 Fundamental Ways to employ a Criminal Legal counselor
- Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart?
- Pick Your Favored kind of sandwich
- Vote in favor of the Top Vegetable for Senior
- Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- Opening Monetary Information: Your Exhaustive Manual for Finding out about Individual budget
- Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico
- From Specialist to Proficient Picture taker: Individual Triumphs
- The Best Computer games Ever
